Skip to content

Evaluation of Sevoflurane Therapy for Autistic Children Based on Comprehensive Magnetic Resonance Technology

Evaluation of Sevoflurane Therapy in Autistic (ASD) Children Based on Comprehensive Magnetic Resonance Technology and Study of Neural Mechanism

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500113854
Enrollment
Unknown
Registered
2025-12-03
Start date
2024-10-08
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autism Spectrum Disorder

Interventions

Sponsors

Guangzhou Medical University Affiliated Women and Children's Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Patients meeting the DSM-V diagnostic criteria for autism spectrum disorder 2. Male or female patients aged 3-18 years, right-handed; 3. Participants must be able to complete all assessments; 4. The parents or legal guardians of the subjects have good reading and understanding skills, and can cooperate with the completion of the relevant assessment scale and follow-up. 5. Evidence of a subject (or a legal representative) signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study and are willing to participate in it.

Exclusion criteria

Exclusion criteria: 1. Other mental disorders other than autism spectrum disorder (such as epilepsy, schizophrenia, attention deficit hyperactivity disorder, stunted growth, cerebral ischemia and hypoxia, cephalitis, or craniocerebral injury; poisoning); 2. Patients with severe physical diseases or other systemic diseases (history of renal, hepatic, metabolic disorders, tumors, infections, organic diseases of the nervous system, endocrine, immunologic diseases); 3. Subjects with serum K+ or Mg2+ beyond the normal range; 4. A history of malignant syndrome or tardive dyskinesia history; 5. Monoamine oxidase antidepressants were administered prior to the study in 2 weeks; 6. Participation in other studies within the last 30 days before the current study begins and /or during study participation.

Design outcomes

Primary

MeasureTime frame
Brain Magnetic Resonance Imaging;Childhood Autism Rating Scale;

Secondary

MeasureTime frame
Autism Treatment Evaluation Checklist;Social responsiveness scale;Repetitive behavior scale-revised;Autism Behavior Checklist;Treatment emergent symptom scale;Caregiver strain questionnaire;

Countries

China

Contacts

Public ContactXuntao Yin

Guangzhou Medical University Affiliated Women and Children's Medical Center

xuntaoyin@gmail.com+86 153 2031 9357

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026